DOCSLIB.ORG

Maternal and Infant Death and the Rvsv-ZEBOV

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Maternal and Infant Death and the Rvsv-ZEBOV See discussions, stats, and author profiles for this publication at: https://www.researchgate.net/publication/337559229 Maternal and Infant Death and the rVSV-ZEBOV Vaccine Through Three Recent Ebola Virus Epidemics-West Africa, DRC Équateur and DRC Kivu: 4 Years of Excluding Pregnant and Lactating... Article in Current Tropical Medicine Reports · December 2019 DOI: 10.1007/s40475-019-00195-w CITATIONS READS 16 80 1 author: David Schwartz formerly Clinical Professor of Pathology Medical College of Georgia Augusta GA. 201 PUBLICATIONS 7,693 CITATIONS SEE PROFILE Some of the authors of this publication are also working on these related projects: Special Zika Virus Issue of the Archives of Pathology & Laboratory Medicine, January 2017 View project Development, clinical trials and implementation of vaccines in pregnancy View project All content following this page was uploaded by David Schwartz on 21 December 2019. The user has requested enhancement of the downloaded file. Current Tropical Medicine Reports https://doi.org/10.1007/s40475-019-00195-w VACCINES IN PREGNANT WOMEN & INFANTS (D SCHWARTZ AND C KRUBINER, SECTION EDITORS) Maternal and Infant Death and the rVSV-ZEBOV Vaccine Through Three Recent Ebola Virus Epidemics-West Africa, DRC Équateur and DRC Kivu: 4 Years of Excluding Pregnant and Lactating Women and Their Infants from Immunization David A. Schwartz1 # The Author(s) 2019 Abstract Purpose of Review Ebola virus infection has one of the highest overall case fatality rates of any viral disease. It has historically had an especially high case mortality rate among pregnant women and infants—greater than 90% for pregnant women in some outbreaks and close to 100 % in fetuses and newborns. The Merck recombinant vaccine against Ebola virus, termed rVSV-ZEBOV, underwent clinical trials during the 2013–2015 West Africa Ebola epidemic where it was found to be 100% efficacious. It was subsequently used during the 2018 DRC Équateur outbreak and in the 2018 DRC Kivu Ebola which is still ongoing, where its efficacy is 97.5 %. Pregnant and lactating women and their infants have previously been excluded from the design, clinical trials, and administration of many vaccines and drugs. This article critically examines the development of the rVSV-ZEBOV vaccine and its accessibility to pregnant and lactating women and infants as a life-saving form of prevention through three recent African Ebola epidemics—West Africa, DRC Équateur, and DRC Kivu. Recent Findings Pregnant and lactating women and their infants were excluded from participation in the clinical trials of rVSV- ZEBOV conducted during the West Africa epidemic. This policy of exclusion was continued with the occurrence of the DRC Équateur outbreak in 2018, in spite of calls from the public health and global maternal health communities to vaccinate this population. Following the onset of the DRC Kivu epidemic, the exclusion persisted. Eventually, the policy was reversed to include vaccination of pregnant and lactating women. However, it was not implemented until June 2019, 10 months after the start of the epidemic, placing hundreds of women and infants at risk for this highly fatal infection. Summary The historical policy of excluding pregnant and lactating women and infants from vaccine design, clinical trials, and implementation places them at risk, especially in situations of infectious disease outbreaks. In the future, all pregnant women, regardless of trimester, breastfeeding mothers, and infants, should have access to the Ebola vaccine. Keywords Vaccine . Vaccination . rVSV-ZEBOV . Ebola virus . Ebola vaccine . West Africa Ebola epidemic . Équateur province Ebola outbreak . Kivu Ebola epidemic . Maternal death . Fetal death . Human rights . Pregnancy complications . Immunization . DRC Ebola epidemics . Exclusion of pregnant women Introduction This article is part of the Topical Collection on Vaccines in Pregnant Women and Infants The case fatality rate (CFR) for Ebola virus is one of the highest of any infectious disease [1, 2]. The initial outbreak * David A. Schwartz of the Ebola virus disease (EVD) occurred in the town of [email protected] Yambuko, Democratic Republic of the Congo (DRC, then called Zaire) in late August of 1976. During that outbreak, 1 Medical College of Georgia, Augusta University, 1950 Grace Arbor 318 people were infected and a shocking 280 died—aCFR Court, Atlanta, GA 30329, USA of 88% over 11 weeks [3•]. In a pattern that was to be repeated Curr Trop Med Rep in subsequent outbreaks, a high percentage of caregivers at the The intentional exclusion of pregnant and lactating women rural Yambuko Mission Hospital also became infected with and their infants from both the clinical trials and subsequent the previously unknown virus—13 of the 17 hospital staff distribution of this vaccine has remained controversial through members (76%) developed the infection and 11 (80%) died all three Ebola epidemics [9, 10, 16, 18, 19, 20•, 21–27, 28••]. [3•]. At about the same time, the World Health Organization This article discusses the scientific, public health, organiza- (WHO) announced that another outbreak of a similar hemor- tional, and humanitarian issues surrounding the withholding rhagic fever was occurring in southern Sudan, centered in of this highly effective immunization from this population at Nzara, between June and November 1976 [4]. Of 284 persons high risk for infection, and future policy directed to the rights with EVD during the Sudanese outbreak, the overall CFR was of pregnant women and their infants to receive life-saving 53%. In 1979, a recurrent but smaller outbreak occurred in the vaccines. same area of Sudan, resulting in 34 infections and 22 deaths— a65%CFR[5]. Since that time, multiple outbreaks of EVD had occurred, Mortality of Ebola Virus Infection with the largest being the 2013–2015 West African Ebola Among Non-vaccinated Pregnant Women epidemic, which began in Guinea and moved across the bor- and Their Infants ders to Liberia and Sierra Leone, eventually resulting in an official case count of 28,616 infected persons and 11,310 There is no evidence that women who are pregnant are more deaths [6]. The approximate overall CFR was 40%, although biologically susceptible to becoming infected with Ebola virus it is generally believed that these metrics understated both the than are non-pregnant individuals [1, 7, 9, 29]. However, both numbers of infected persons as well as deaths from EVD prior to and during the West Africa Ebola virus epidemic, it during this epidemic [1, 7]. In August 2015, an experimental was generally believed that once a pregnant woman acquired vaccine for the Ebola virus, the rVSV-ZEBOV produced by Ebola infection, she was more likely to have a fatal outcome Merck, became available as part of a cluster-randomized clin- than were non-pregnant persons [7], and that based upon prior ical trial for persons at risk during the West African Ebola outbreaks that greater than 90% of infected pregnant women epidemic [8]. Family members and other contacts of infected and 100% of fetuses would likely die as a result of EVD [1, persons, healthcare givers, and persons in contact with the 29]. In an interview performed early in the epidemic, a repre- bodies of EVD victims were all eligible for receiving the sentative from a non-governmental organization had opined new vaccine—all, that is, except for pregnant and lactating that the survival rate for expectant mothers was virtually zero women and their infants. The theoretical risk that the replica- [30]. In a report published in 2015 [31], the probability for tion competent vaccine virus could cross the placenta and maternal and infant survival of EVD was summarized as harm the fetus or cause other complications to the mother follows, resulted in their exclusion from receiving the vaccine—in this case, with a disease that had a high maternal mortality rate and an essentially 100% case fatality rate among infected fetuses “Present data suggests that maternal mortality remains and newborns [9–12]. high (approximately 95%) and peri-natal mortality vir- In 2018, Ebola reemerged in the country in which it was tually 100% for infected pregnant women.” first recognized—two back-to-back outbreaks began in the DRC. The first occurred in Équateur province of northwestern During the initial EVD outbreak in Yambuku, ten live in- DRC, lasting from May until June. When the end of the out- fants were born to mothers who subsequently died of the in- break was declared on July 24th, there had been a total of 38 fection. All of these children also died within 19 days [9, 20•]. confirmed and 16 probable EVD infections, 33 deaths, and a Analysis of all EVD outbreaks prior to the West Africa epi- CFR of 61% [13]. Although greater than 2 years had passed demic by Bebell revealed that there were 111 cases of pregnant since the final case in West Africa was reported, during the women reported who had acquired the infection, with an ag- Équateur province outbreak the rVSV-ZEBOV vaccine was gregate CFR of 86% [7]. The highest maternal and infant administered but pregnant and lactating women and infants CFRs reported for EVD occurred during the 1995 outbreak were still excluded. The second, and significantly larger, in Kikwit, Zaire, in which only 1 of 15 EVD-infected women EVD epidemic began at the start of August 2018 in North survived (CFR 93%) [19]. However, it should be noted that all Kivu province [14]. This epidemic is still continuing, has in- of these women were probably infected via injection with con- fected 3296 persons and caused 2194 deaths [15], and is the taminated needles and that this parenteral route of transmission second most widespread since the discovery of the virus in is hypothesized to have contributed to the high CFR. All of the 1976. Once again, the rVSV-ZEBOV was administered to pregnant women during the Kikwit EVD outbreak presented persons at risk but excluded pregnant and lactating women with severe hemorrhage.
Load more

Recommended publications
  • A Multicenter, Multi-Outbreak, Randomized, Controlled Safety And
    2018 Ebola MCM RCT Protocol Page 1 of 92 IND#: 125530 CONFIDENTIAL 4 October 2019, version 7.0 A Multicenter, Multi-Outbreak, Randomized, Controlled Safety and Efficacy Study of Investigational Therapeutics for the Treatment of Patients with Ebola Virus Disease Short Title: 2018 Ebola MCM RCT Protocol Sponsored by: Office of Clinical Research Policy and Regulatory Operations (OCRPRO) National Institute of Allergy and Infectious Diseases 5601 Fishers Lane Bethesda, MD 20892 NIH Protocol Number: 19-I-0003 Protocol IND #: 125530 ClinicalTrials.gov Number: NCT03719586 Date: 4 October 2019 Version: 7.0 CONFIDENTIAL This document is confidential. No part of it may be transmitted, reproduced, published, or used by other persons without prior written authorization from the study sponsor and principal investigator. 2018 Ebola MCM RCT Protocol Page 2 of 92 IND#: 125530 CONFIDENTIAL 4 October 2019, version 7.0 KEY ROLES DRC Principal Investigator: Jean-Jacques Muyembe-Tamfum, MD, PhD Director-General, DRC National Institute for Biomedical Research Professor of Microbiology, Kinshasa University Medical School Kinshasa Gombe Democratic Republic of the Congo Phone: +243 898949289 Email: [email protected] Other International Investigators: see Appendix E Statistical Lead: Lori Dodd, PhD Biostatistics Research Branch, DCR, NIAID 5601 Fishers Lane, Room 4C31 Rockville, MD 20852 Phone: 240-669-5247 Email: [email protected] U.S. Principal Investigator: Richard T. Davey, Jr., MD Clinical Research Section, LIR, NIAID, NIH Building 10, Room 4-1479, Bethesda,
    [Show full text]
  • Accelerating R&D for Emerging Infectious Diseases: Lessons
    Accelerating R&D for Emerging Infectious Diseases: Lessons Learnt From Ebola Chao Li China CDC Jingyi Chen Harvard University Jiyan Ma Peking University Health Science Centre Yangmu Huang ( [email protected] ) Peking University Health Science Centre https://orcid.org/0000-0002-3660-1276 Research Article Keywords: Ebola Virus Disease, Emerging Infectious Disease, Research and Development Posted Date: July 2nd, 2020 DOI: https://doi.org/10.21203/rs.3.rs-38612/v1 License: This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License Page 1/12 Abstract Objective: The R&D explosion for Ebola virus disease (EVD) during the 2014-2016 outbreak led to the successful development of high-quality vaccines performed by China and the U.S. This study aims to compare the R&D activities of Ebola-related medical products in two countries, as a way to present the inuential factors of R&D for emerging infectious disease (EID) and to provide suggestions for timely and ecient R&D response to the COVID-19 pandemic. Methods: In this comparative study, R&D activities were analyzed in terms of research funding, scientic research outputs, R&D timeline, and government incentive and coordinated mechanisms. Quantitative analysis was performed using data retrieved from national websites, clinical trial registries and databases.Qualitative semi-structured interviews were conducted to explore perspectives of fteen key informants from EID eld, especially of those involved in Ebola product development. Findings: The funding gap between China and the U.S. was signicant before 2014 and narrowed after the Ebola outbreak. Both research teams started basic studies prior to the Ebola outbreak; however, the U.S.
    [Show full text]
  • Joint Press Release Between Africa Cdc and Who on The
    Press Release No…… JOINT PRESS RELEASE BETWEEN AFRICA CENTRES FOR DISEASE CONTROL AND PREVENTION AND THE WORLD HEALTH ORGANIZATION ON THE SITUATION OF EBOLA VIRUS DISEASE OUTBREAK IN THE DEMOCRATIC REPUBLIC OF CONGO Addis Ababa, Ethiopia & Brazzaville, Republic of Congo, 19 July 2019. On 17 July 2019, the World Health Organisation (WHO) Director General, Dr Tedros Adhanom GheBreyesus, declared the ongoing EBola virus disease (EVD) outbreak in the Democratic RepuBlic of Congo (DRC) as a Public Health Emergency of International Concern (PHEIC). A PHEIC is defined in the IHR (2005) as, “an extraordinary event which is determined to constitute a public health risk to other States through the international spread of disease and to potentially require a coordinated international response”i. As of 18 July 2019, the Ministry of PuBlic Health of the DRC reported 2,532 cases (2,438 confirmed and 94 probable) with 1,705 deaths and 718 cured. In declaring the DRC EVD outbreak a PHEIC, the WHO took into consideration the first confirmed case in Goma, a city of almost two million inhaBitants and close to the border with Rwanda, and the gateway to the rest of DRC and the world. Between 2009 and 2019, there have been five PHEIC declarations.ii Declaration of a PHEIC is a call to action. Therefore, it is time for the African continent and indeed the world to redouble our efforts in solidarity with the DRC to end this outBreak and Build a stronger health system. In view of the PHEIC declaration, Africa Centres for Disease Control and Prevention (Africa CDC) and the WHO Regional Office for Africa would like to reiterate the need for all Member States to adhere to the recommendations made, emphasising the following: • No country should close its borders or place any restrictions on travel and trade, including general quarantine of travelers from the Ebola-affected countries, currently the DRC.
    [Show full text]
  • The Philippine National Deployment and Vaccination Plan for COVID-19 Vaccines
    The Philippine National Deployment and Vaccination Plan for COVID-19 Vaccines Interim Plan January 2021 Acknowledgement The Philippine National Deployment and Vaccination Plan for COVID-19 Vaccines (NDVP) was developed by the Philippine Government under the leadership of President Rodrigo Roa Duterte, and under the guidance of Health Secretary Franscisco T. Duque III and COVID-19 Vaccine Cluster Chair, Secretary Carlito G. Galvez Jr. All government agencies under the COVID-19 Vaccine Cluster have contributed in the development of this plan: Office of the President (OP), Office of the Chief Presidential Legal Counsel (OCPLC), Department of Health (DOH), Department of Science and Technology (DOST), Food and Drug Administration (FDA), Research Institute for Tropical Medicine (RITM), Department of Trade and Industry (DTI), Department of Foreign Affairs (DFA), National Development Company (NDC), Department of Finance (DOF), Department of Budget and Management (DBM), Department of Interior and Local Government (DILG), Department of Social Welfare and Development (DSWD), Department of Education (DepEd), Department of National Defense (DND), Department of Information and Communications Technology (DICT), Department of Transportation (DOTr), Department of Justice (DOJ), Department of Labor and Employment (DOLE), Armed Forces of the Philippines (AFP), Office of Civil Defense (OCD), Philippine National Police (PNP), Bureau of Corrections (BuCor), Bureau of Jail Management and Penology (BJMP), and Task Group Resource Management and Logistics (TGRML) under the National Task Force Against COVID-19. The Task Group COVID-19 Immunization Program, under the guidance of Undersecretary Myrna C. Cabotaje and Director Napoleon Arevalo, consolidated and ensured the completion of this plan. Further, special thanks to the following for doing the technical writing, editing and proofreading: Dr.
    [Show full text]
  • World Journal of Pharmaceutical Research Nandi Et Al
    World Journal of Pharmaceutical Research Nandi et al. World Journal of Pharmaceutical SJIF ImpactResearch Factor 8.084 Volume 9, Issue 6, 1265-1287. Review Article ISSN 2277– 7105 RNA GENOME OF EBOLA VIRION AND VACCINATION BY MONOCLONAL ANTIBODIES *Kushal Nandi and Dr. Dhrubo Jyoti Sen Department of Pharmaceutical Chemistry, School of Pharmacy, Techno India University, Salt Lake City, Sector-V, EM-4, Kolkata-700091, West Bengal, India. ABSTRACT Article Received on 06 April 2020, Ebola, also known as Ebola virus disease (EVD), is a viral Revised on 27 April 2020, haemorrhagic fever of human and other primates caused by Accepted on 18 May 2020 DOI: 10.20959/wjpr20206-17705 ebolaviruses. Signs and symptoms typically start between two days and three weeks after contracting the virus with a fever, sore throat, muscular pain, and headaches. Vomiting, diarrhoea and rash *Corresponding Author usually follow, along with decreased function of the liver and kidneys. Kushal Nandi Department of At this time, some people begin to bleed both internally and Pharmaceutical Chemistry, externally. The disease has a high risk of death, killing 25% to 90% of School of Pharmacy, those infected, with an average of about 50%. This is often due to low Techno India University, blood pressure from fluid loss, and typically follows six to 16 days Salt Lake City, Sector-V, after symptoms appear. The disease was first identified in 1976, in two EM-4, Kolkata-700091, West Bengal, India. simultaneous outbreaks: one in Nzara (a town in South Sudan) and the other in Yambuku (Democratic Republic of the Congo), a village near the Ebola River from which the disease takes its name.
    [Show full text]
  • 20200430 the Tragedy of Missed Opportunities
    The Tragedy of Missed Opportunities THE TRAGEDY OF MISSED OPPORTUNITIES COVID-19 Human Costs and Economic Damage Contents|1 The Tragedy of Missed Opportunities This report is authored by Dan Steinbock, Ph.D. is the founder of Difference Group Ltd (www.differencegroup.net). He has served at the India, China and America Institute (USA), Shanghai Institutes for International Studies (China) and the EU Center (Singapore). Prologue I have analyzed the COVID-19 prospects ever since the ‘mystery pneumonia with an unknown etiology’ was discovered in Wuhan, Hubei, at the end of December 2019. The first maJor international pandemic since the Spanish flu is likely to cause millions of infections and hundreds of thousands of deaths, and a global contraction that will prove far more consequential than the 2008/9 global recession. Despite China’s relatively successful battle to contain the outbreak, and the World Health Organization’s (WHO) international alerts and repeated warnings, the mobilization against the outbreak in Europe and the United States began weeks too late as several critical opportunities were missed. That’s why I wrote the report at hand. It is important to understand the underlying forces behind maJor policy mistakes to avoid new mistakes and overcome future challenges. It is heavily documented to show how critical pathways were missed. “For too long, the world has operated on a cycle of panic and neglect,” WHO director-general Dr Tedros said over a year ago, months before the novel coronavirus outbreak. “We throw money at an outbreak, and when it’s over, we forget about it and do nothing to prevent the next one” And he warned: “This is frankly difficult to understand, and dangerously short-sighted.” COVID-19 is not the first pandemic; nor will it be the last one.
    [Show full text]
  • 2020 05 07 NEJM Ebola.Pdf
    The new england journal of medicine Review Article Edward W. Campion, M.D., Editor Ebola Heinz Feldmann, M.D., Armand Sprecher, M.D., and Thomas W. Geisbert, Ph.D.​​ From the Laboratory of Virology, Division bola virus (EBOV) was the best-known and most extensively stud- of Intramural Research, National Insti- ied member of the Filoviridae family (Mononegavirales order) long before tute of Allergy and Infectious Diseases, Rocky Mountain Laboratories, Hamilton, the shattering 2013–2016 West African epidemic. The virologic taxon Filo- MT (H.F.); Médecins sans Frontières, E viridae was defined in 1982 and subsequently amended regularly to accommodate Brussels (A.S.); and the Department of changes.1,2 These amendments and the unfortunate renaming of commonly used Microbiology and Immunology and Gal- veston National Laboratory, University terms has made the filovirus taxonomy confusing. Today, EBOV refers to the spe- of Texas Medical Branch at Galveston, cific member virus of the type species Zaire ebolavirus in the genus ebolavirus Galveston (T.W.G.). Address reprint re- (Fig. 1). quests to Dr. Feldmann at Rocky Moun- tain Laboratories, 903 S. 4th St., Hamil- The history of filoviruses largely involves human outbreaks (Fig. 1). Marburg ton, MT 59840, or at feldmannh@ ​­niaid virus (MARV) was the first filovirus to be discovered, in 1967.3 EBOV and Sudan . nih . gov. virus (SUDV) were codiscovered in 1976 in the Democratic Republic of Congo N Engl J Med 2020;382:1832-42. (DRC) and South Sudan, respectively.4,5 Subsequently, two additional ebolaviruses DOI: 10.1056/NEJMra1901594 were found to be pathogenic in humans: Taï Forest virus (TAFV) in Côte d’Ivoire Copyright © 2020 Massachusetts Medical Society.
    [Show full text]
  • Data Sharing During the West Africa Ebola Public Health Emergency: Case Study Report November 2018
    Data Sharing during the West Africa Ebola Public Health Emergency: Case Study Report November 2018 1. Introduction a. Background to the 2013-15 outbreak: On December 6, 2013, Emile Ouamouno, a 2-year-old from Meliandou, a small village in the Guinea forestière, died after four days of suffering from vomiting, fever, and black stool.1 The cause of his infection is unknown, although he is now widely considered to be the index case for the outbreak of Ebola hemorrhagic fever now Ebola Virus Disease (EVD). Within a month, the child’s sister, mother, and grandmother died after experiencing similar symptoms.3 The funeral for the latter was attended by a midwife who passed the disease to relatives in another village, and to a health care worker treating her.4 That health care worker was treated at a hospital in Macenta, about 80 kilometers (50 miles) east. A doctor who treated her contracted Ebola. The doctor then passed it to his brothers in Kissidougou, 133 kilometers (83 miles) away. 4 Although the outbreak of EVD originated in Guinea, between December 2013 and March 2014, it spread more rapidly in the eastern regions of Sierra Leone and then in North Central Liberia, followed by Nzérékoré in Guinea. 5 Between December 2013 and April 10, 2016, a total of 28,616 suspected, probable, and confirmed cases of Ebola virus disease (EVD) were reported. 5 A total of 11,310 deaths were attributed to the outbreak. 5 The largest numbers of cases and deaths occurred in Guinea, Liberia, and Sierra Leone, but 36 cases were reported from Italy, Mali, Nigeria, Senegal, Spain, the United Kingdom, and the United States.6 After reaching a peak of 950 confirmed cases per week in September 2014, the incidence dropped precipitously toward the end of that year.
    [Show full text]
  • Ebola Virus Disease
    PRIMER Ebola virus disease Shevin T. Jacob1,2, Ian Crozier3, William A. Fischer II4, Angela Hewlett5, Colleen S. Kraft6, Marc-Antoine de La Vega7, Moses J. Soka8, Victoria Wahl9, Anthony Griffiths10, Laura Bollinger11 and Jens H. Kuhn11 ✉ Abstract | Ebola virus disease (EVD) is a severe and frequently lethal disease caused by Ebola virus (EBOV). EVD outbreaks typically start from a single case of probable zoonotic transmission, followed by human-to-human transmission via direct contact or contact with infected bodily fluids or contaminated fomites. EVD has a high case–fatality rate; it is characterized by fever, gastrointestinal signs and multiple organ dysfunction syndrome. Diagnosis requires a combination of case definition and laboratory tests, typically real-time reverse transcription PCR to detect viral RNA or rapid diagnostic tests based on immunoassays to detect EBOV antigens. Recent advances in medical countermeasure research resulted in the recent approval of an EBOV-targeted vaccine by European and US regulatory agencies. The results of a randomized clinical trial of investigational therapeutics for EVD demonstrated survival benefits from two monoclonal antibody products targeting the EBOV membrane glycoprotein. New observations emerging from the unprecedented 2013–2016 Western African EVD outbreak (the largest in history) and the ongoing EVD outbreak in the Democratic Republic of the Congo have substantially improved the understanding of EVD and viral persistence in survivors of EVD, resulting in new strategies toward prevention of infection and optimization of clinical management, acute illness outcomes and attendance to the clinical care needs of patients. To date, 12 distinct filoviruses have been described1. outbreak. All FVD outbreaks, with the exception of that The seven filoviruses that have been found in humans caused by TAFV, were characterized by extremely high belong either to the genus Ebolavirus (Bundibugyo virus case–fatality rates (CFRs, also known as lethality).
    [Show full text]
  • Parallel Outbreaks of Deadly Pathogens
    Review Parallel Outbreaks of Deadly Pathogens (SARS-CoV-2, H5N8, EVD, Black Fungi) around East Africa and Asia in 2021: Priorities for Outbreak Management with Socio-Economic and Public Health Impact Afroza Khan 1,† , Nayeema Talukder Ema 1,†, Nadira Naznin Rakhi 1, Otun Saha 1,† , Tamer Ahamed 2 and Md. Mizanur Rahaman 1,* 1 Department of Microbiology, University of Dhaka, Dhaka 1000, Bangladesh; [email protected] (A.K.); [email protected] (N.T.E.); [email protected] (N.N.R.); [email protected] (O.S.) 2 Norwich Medical School, University of East Anglia, Norwich Research Park, Norwich NR4 7TJ, Norfolk, UK; [email protected] * Correspondence: [email protected]; Tel.: +88-017-9658-5290 † Equal Contributions. Abstract: Concurrent waves of coronavirus disease, Ebola virus disease, avian influenza A, and black fungus are jeopardizing lives in some parts of Africa and Asia. From this point of view, this review aims to summarize both the socio-economic and public health implications of these parallel outbreaks along with their best possible management approaches. Online databases (PubMed/PMC/Medline, Publons, ResearchGate, Scopus, Google Scholar, etc.) were used to collect the necessary information regarding Citation: Khan, A.; Ema, N.T.; Rakhi, these outbreaks. Based on the reports published and analyses performed so far, the long-lasting impacts N.N.; Saha, O.; Ahamed, T.; Rahaman, caused by these simultaneous outbreaks on global socio-economical and public health status can be M.M. Parallel Outbreaks of Deadly conceived from the past experiences of outbreaks, especially the COVID-19 pandemic. Moreover, Pathogens (SARS-CoV-2, H5N8, EVD, Black Fungi) around East Africa and prolonged restrictions by the local government may lead to food insecurity, global recession, and an Asia in 2021: Priorities for Outbreak enormous impact on the mental health of people of all ages, specifically in developing countries.
    [Show full text]
  • Fighting Novel Diseases Amidst Humanitarian Crises
    Georgetown University Law Center Scholarship @ GEORGETOWN LAW 2019 Fighting Novel Diseases amidst Humanitarian Crises Lawrence O. Gostin Georgetown University Law Center, [email protected] Neil R. Sircar Georgetown University Law Center, [email protected] Eric A. Friedman Georgetown University Law Center, [email protected] This paper can be downloaded free of charge from: https://scholarship.law.georgetown.edu/facpub/2141 https://ssrn.com/abstract=3340144 Hastings Center Report, January-February 2019, 6-9. This open-access article is brought to you by the Georgetown Law Library. Posted with permission of the author. Follow this and additional works at: https://scholarship.law.georgetown.edu/facpub Part of the Health Law and Policy Commons, and the International Humanitarian Law Commons at law departure” of U.S. personnel even from Kinshasa, where the CDC was working with the DRC Ministry of Health to Fighting Novel Diseases track cases in North Kivu.6 The Kin- shasa Ebola operations center may be amidst Humanitarian Crises left with as little as one CDC expert. Other countries, such as France and the United Kingdom, have followed the U.S. lead and have also withdrawn by Lawrence O. Gostin, Neil R. Sircar, and Eric A. Friedman from North Kivu. The Trump adminis- tration apparently has adopted a policy he Democratic Republic of the could accelerate and spread within and of zero risk tolerance, fearing a “Beng- Congo is facing two crises: a beyond the DRC.2 Guerrilla and rebel hazi-style” attack. In a vicious cycle, the Tpotentially explosive Ebola epi- groups, notably the Allied Democratic few brave health workers remaining are demic and a major insurgency.
    [Show full text]
  • Quantification of Ebola Virus Replication Kinetics in Vitro
    Quantification of Ebola virus replication kinetics in vitro Laura E. Liaoa,1 Jonathan Carruthersb,1 Sophie J. Smitherc CL4 Virology Teamc,2 Simon A. Wellerc Diane Williamsonc Thomas R. Lawsc Isabel Garc´ıa-Dorivald Julian Hiscoxd Benjamin P. Holdere Catherine A. A. Beaucheminf,g Alan S. Perelsona Mart´ın L´opez-Garc´ıab Grant Lytheb John Barrh Carmen Molina-Par´ısb,3 a Theoretical Biology and Biophysics, Los Alamos National Laboratory, Los Alamos, NM, USA 87545 b Department of Applied Mathematics, School of Mathematics, University of Leeds, Leeds LS2 9JT, UK c Defence Science and Technology Laboratory, Salisbury SP4 0JQ, UK d Institute of Infection and Global Health, University of Liverpool, Liverpool, L69 7BE, UK e Department of Physics, Grand Valley State University, Allendale, MI, USA 49401 f Department of Physics, Ryerson University, Toronto, ON, Canada M5B 2K3 g Interdisciplinary Theoretical and Mathematical Sciences (iTHEMS) Research Program at RIKEN, Wako, Saitama, Japan, 351-0198 h School of Molecular and Cellular Biology, University of Leeds, Leeds LS2 9JT, UK 1 These authors contributed equally to this work. 2 Membership list can be found in the Acknowledgments section. 3 [email protected] Abstract Mathematical modelling has successfully been used to provide quantitative descriptions of many viral infections, but for the Ebola virus, which requires biosafety level 4 facilities for experimentation, modelling can play a crucial role. Ebola modelling efforts have primarily focused on in vivo virus kinetics, e.g., in animal models, to aid the development of antivirals and vaccines. But, thus far, these studies have not yielded a detailed specification of the infection cycle, which could provide a foundational description of the virus kinetics and thus a deeper understanding of their clinical manifestation.
    [Show full text]